An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient.
Journal
Case reports in oncological medicine
ISSN: 2090-6706
Titre abrégé: Case Rep Oncol Med
Pays: United States
ID NLM: 101581035
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
08
2019
accepted:
23
04
2020
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
epublish
Résumé
Immunotherapy with immune checkpoint inhibitors (ICI) is a new option of treatment in a growing range of neoplasms. In addition to an antitumor effect, ICI are associated with autoimmune reactions resulting in a wide spectrum of toxicities that have not been seen in patients receiving chemotherapy. In this article, we present a case of a patient with advanced lung adenocarcinoma who developed an EDTA-dependent pseudothrombocytopenia (PTCP) during pembrolizumab therapy. To the best of our knowledge, this is the first reported case of EDTA-dependent PTCP occurring during immunotherapy treatment of nonsmall lung cell cancer with ICI. The phenomenon of EDTA-dependent PTCP may prompt clinical decisions, as unnecessary transfusions or even exclusion from pembrolizumab therapy. Therefore, it is important to be aware of PTCP as a possible side effect of this therapy.
Identifiants
pubmed: 32455036
doi: 10.1155/2020/4196178
pmc: PMC7232686
doi:
Types de publication
Case Reports
Langues
eng
Pagination
4196178Informations de copyright
Copyright © 2020 Kinga Krukowska et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this article.
Références
Drug Des Devel Ther. 2018 Jun 08;12:1645-1657
pubmed: 29922039
J Clin Oncol. 2001 Feb 15;19(4):1137-46
pubmed: 11181679
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Oncol Lett. 2012 Jul;4(1):86-88
pubmed: 22807967
BMJ Case Rep. 2014 Jun 20;2014:
pubmed: 24951601
Transfus Med Hemother. 2017 Nov;44(6):426-428
pubmed: 29344020
Oncology (Williston Park). 2015 Apr;29(4):282-94
pubmed: 25952492
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Oncology (Williston Park). 2015 Apr;29(4):297-8
pubmed: 25952494
Eur J Cancer. 2017 Aug;81:116-129
pubmed: 28623775
Clin Appl Thromb Hemost. 2012 Nov;18(6):645-9
pubmed: 22395573
Eur J Cancer. 2016 Feb;54:172-174
pubmed: 26687374
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
Am J Hematol. 2010 Nov;85(11):909-10
pubmed: 20815078
Neurology. 2003 Aug 26;61(4):579-80
pubmed: 12939450
Thromb Res. 2014 May;133 Suppl 2:S63-9
pubmed: 24862148
Clin Chem Lab Med. 2012 Aug;50(8):1281-5
pubmed: 22868791
J Immunother Cancer. 2017 Feb 21;5:8
pubmed: 28239462
Am J Hematol. 1995 Oct;50(2):103-9
pubmed: 7572988
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Lancet Haematol. 2019 Jan;6(1):e48-e57
pubmed: 30528137
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Oncol Res Treat. 2017;40(10):621-622
pubmed: 28950270
Am J Transl Res. 2018 Aug 15;10(8):2234-2245
pubmed: 30210667